Switch View
© BusinessWire
20.10.2025
ISIN: US07725L1026
BeOne Medicines Ltd.
ONC
LISTED
NASDAQ
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in B...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: NL0010872495
ProQR Therapeutics NV
PRQR
LISTED
NASDAQ
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
News Preview
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that following review under the new European Medicines Agency (E...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US71722W1071
Phathom Pharmaceuticals Inc
PHAT
LISTED
NASDAQ
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
News Preview
FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 fi...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
20.10.2025
ISIN: US15713L1098
CervoMed Inc.
CRVO
LISTED
NASDAQ
CervoMed to Present at the Emerging Growth Conference
News Preview
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
20.10.2025
ISIN: US68401U2042
OptimizeRx Corp
OPRX
LISTED
NASDAQ
OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET
News Preview
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US3847471014
Grail, Inc.
GRAL
LISTED
NASDAQ
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
News Preview
One-Third of Participants Initially Believed to Have a False-Positive Result Were Later Diagnosed With Cancer During Follow Up
Updated Positive Predictive Value of Galleri in This Symptomatic Populati...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
News Preview
Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 months in published meta-analysis of metastatic uveal melanoma in the first-line setting
Median progression free survival (PFS) of 7.0 months
Confirmed...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CA10778Y1043
BriaCell Therapeutics Corp.
BCT
LISTED
TSX
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces encouraging clinical biomarker data in its ongoing pivotal...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US21900C3088
CorMedix Inc
CRMD
LISTED
NASDAQ
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
News Preview
‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
News Preview
Oral presentation to highlight 24-week efficacy and safety data...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
News Preview
Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US34965KAA51
Fortrea Holdings, Inc.
FTRE
LISTED
NASDAQ
Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt
News Preview
DURHAM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it has commenced a debt tender offer (the “Tender Offer”) to purchase for cash up to $75,744,000 (the “Maximum Amount”) in aggregate purchase price of the Company’s outstanding 7.500...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
20.10.2025
ISIN: US05280R1005
Autolus Therapeutics plc
AUTL
LISTED
NASDAQ
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis
News Preview
The first patient has been dosed in the Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) in patients with progressive multiple sclerosis....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US03753U1060
Apellis Pharmaceuticals Inc
APLS
LISTED
NASDAQ
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
News Preview
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI® (pegcetacoplan), a C3 inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune complex membranop...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US09076D1019
Southwest Casino Corp.
SWCC
LISTED
OTC
AI Maverick Intel, Inc. Announces New Trading Symbol “AIMV” Effective Oct. 20, 2025
News Preview
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – AI Maverick Intel Inc. (OTC: AIMV), a technology-driven innovator focused on redefining how businesses acquire and engage customers through artificial intelligence, today announced that effective Oct. 20, 2025, the Company’s common shares will commence trading on the OTC Market under its new t...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
News Preview
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CA17104U1021
Christina Lake Cannabis Corp
CLC
LISTED
CSE
Christina Lake Cannabis Announces Credit Facility and Lease Agreement
News Preview
Christina Lake Cannabis announces $1.5M secured credit facility and 18-month equipment lease...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CA58490H1073
Medicenna Therapeutics Corp
MDNA
LISTED
TSX
Medicenna Therapeutics Announces Participation in Upcoming Conferences
News Preview
TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases is pleased to announce its participation...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Company") (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promu...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rul...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH Investors Have Opportunity to Lead Molina Healthcare, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina" or "the Company") (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MOH
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Molina Healthcare, Inc. ("Molina " or "the Company") (NYSE: MOH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securiti...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.10.2025
ISIN: US6300872032
NanoViricides, Inc.
NNVC
LISTED
XASE
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
News Preview
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in a humanized animal model. The Company announces that NV-387 can now be made available for emergency use...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: CNE1000048G6
Remegen Co., Ltd.
9995
LISTED
HKSE
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
News Preview
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by RemeGen Co., Ltd. was...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nutex Health Inc. ("Nutex" or "the Company") (NASDAQ: NUTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US30161Q1040
Exelixis Inc
EXEL
LISTED
NASDAQ
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the stud...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.10.2025
ISIN: US85859W1027
Stemtech Corporation
STEK
LISTED
OTC
Stemtech Corporation Backorders Filled
News Preview
NAPLES, FL / ACCESS Newswire / October 20, 2025 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, announces core products are available for shipment after overcoming challenges with supply delivery and manufacturing. Stemtech Corporation, a Nevada USA company (OTCQB:STEK).Stemtech Corporation Chairman & CEO, Charles...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG0330A1013
Alphamab Oncology
9966
LISTED
HKSE
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
News Preview
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy design...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG0330A1013
Alphamab Oncology
9966
LISTED
HKSE
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
News Preview
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colorectal cancer (mCRC...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US6323071042
Natera Inc
NTRA
LISTED
NASDAQ
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The findings demonstrate that Signatera can expand the adjuvant treatment window and guide the use of adjuvant atezolizumab (Tec...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0005175080
Transgene SA
TNG
LISTED
EURONEXT
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
News Preview
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
News Preview
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for people with muscle-invasive bladder cancer (MIBC) who are at risk of recurrence after surgery (cystectomy) and have detectable circulating tumour DNA (ctDN...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
News Preview
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for el...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
News Preview
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
If you suffered losses in Baxter between February 23, 2022 and July 30, 2025 and would...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG1996C1006
CARsgen Therapeutics Holdings Limited
2171
LISTED
HKSE
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
News Preview
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous C...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
News Preview
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.
- The ultra-long-acting SQ de...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG2588M1006
Cstone Pharmaceuticals
2616
LISTED
HKSE
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
News Preview
SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary P...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG0520K1094
Ascletis Pharma Inc.
1672
LISTED
HKSE
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
News Preview
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.
- The ultra-long-acting SQ de...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.10.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Recognition of Patentability of Claims
News Preview
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SE...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: JP3942400007
Astellas Pharma Inc
45030
LISTED
XJPX
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
News Preview
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area
Study results found no new safety signals and no cases of retinal vasculitis or occlu...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
ISIN: US03969F1093
Arcus Biosciences Inc
RCUS
LISTED
NYSE
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
News Preview
Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain o...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ISIN: KYG2280A1076
Clover Biopharmaceuticals, Ltd.
2197
LISTED
HKSE
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
News Preview
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment of Nicholas Jackson, Ph.D., as...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
News Preview
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (P...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
NEW YORK, Oct. 19, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) and certain of its officers....
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
News Preview
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso's first-in-cl...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
News Preview
Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001.
The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination therap...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as par...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
News Preview
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients
New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across addi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
News Preview
Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated promising clinical activity in patients with previously treated advanced solid tumors refractory to standard treatment. These data were presented today during a proffered paper session (917O) at the 2025 European Society for Medical Oncology...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
News Preview
Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in a...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
